Survival Benefit of Enzalutamide Plus ADT in mHSPC by admin_63069 | May 7, 2022 | News You Can Use Results from the phase 3 ARCHES trial confirm the survival benefit of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
